Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab vs Cisplatin with Radiotherapy in NPC
NCT02012062Phase 3Completed
- Sponsor
- Fudan University
- Start
- Jul 2012
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Started Jul 2012; status: completed.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02012062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012062.